What: Shares of medical device manufacturer Thoratec
So what: After the market closed on Friday, Thoratec competitor HeartWare
Now what: For obvious reasons, this is all potentially good news for Thoratec, as it may now have more time to build the HeartMate II's footprint before it has to deal with competition from HeartWare. Wall Street also helped bolster the excitement today as an analyst at Lazard noted that it increased its pump-sales forecast for Thoratec, while an analyst at Leerink Swann boosted the company's shares to "outperform."
Want to keep up to date on these stocks?
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.